ACIP Votes Unanimously to Recommend Nirsevimab
Today, ACIP voted unanimously (10 YES – 0 NO for all votes) to recommend nirsevimab for use in infants <8 months born or entering their first RSV season, and for children aged 8-19 months who are at increased risk of RSV disease entering their second RSV season (agenda and slides). The Committee also voted for the inclusion of nirsevimab in VFC: Infants aged <8 months born during or entering their first RSV reason are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5kg) Children aged 8-19 months who are at Read More …